Skip to Main Content

Author Details

Raghwa Sharma
Westmead Hospital
2004
50
27
PMIDPaper TitleJournal TitlePublished Year
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
35735440Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review.Curr Oncol2022
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
31239549A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.Mod Pathol2019
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
29854515A Vaginal Angiomyofibroblastoma as a Rare Cause of a Prolapsing Vaginal Mass: A Case Report and Review of the Literature.Case Rep Obstet Gynecol2018
30062862Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2018
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
29531130Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev2018
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
29049607Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.JAMA Oncol2017
28677147Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.Int J Cancer2017
27031538Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.Melanoma Res2016
24134067Localized cutaneous immunoglobulin G4.Int J Dermatol2015
26506417Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Oncotarget2015
26037119Fungal Inositol Pyrophosphate IP7 Is Crucial for Metabolic Adaptation to the Host Environment and Pathogenicity.mBio2015
25748298Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.J Am Acad Dermatol2015
24505588What is your diagnosis? eruptive syringoma.Cutis2014
25316818Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Clin Cancer Res2014
24513809Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis.Clin Immunol2014
23557327Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.Pigment Cell Melanoma Res2013
23619586Gastrointestinal amyloidosis associated with Schnitzler's syndrome.Pathology2013
22156613Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.Clin Cancer Res2012
23031375Kikuchi-Fujimoto disease with cutaneous presentation in a patient with subacute cutaneous lupus erythematosus.Dermatol Online J2012
22962325Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.Mol Cancer Ther2012
22804352Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Br J Dermatol2012
22833082Ovarian teratoma associated with anti-N-methyl D-aspartate receptor encephalitis: a report of 5 cases documenting prominent intratumoral lymphoid infiltrates.Int J Gynecol Pathol2012
22435737Plexiform fibrohistiocytic tumour: morphological changes and challenges in assessment of recurrent and metastatic lesions.Histopathology2012
21423607Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.PLoS One2011
21864259Anti-arthritic effects of immunomodulatory peptide injected in joints.Curr Drug Deliv2011
21976534Copy number aberrations in benign serous ovarian tumors: a case for reclassification?Clin Cancer Res2011
19117973The histological features of intestinal spirochetosis in a series of 113 patients.Int J Surg Pathol2010
21080881Dieulafoy's disease of the bronchus.Pathology2010
20546349Melanoma exhibiting cartilaginous differentiation.Histopathology2010
20633792Cutaneous epithelioid angiosarcoma occurring at a peristomal site.J Am Acad Dermatol2010
20632833Fibrosarcomatous variant of dermatofibrosarcoma protuberans showing COL1A1-PDGFB gene fusion, detected using a novel and disease-specific RT-PCR protocol.Pathology2010
20229506Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.J Pathol2010
20350228Composite phaeochromocytoma-ganglioneuroma, an uncommon entity: report of two cases.Pathology2010
18000712Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors).Ann Surg Oncol2008
19010816Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.Mol Cancer Res2008
18980987Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.Clin Cancer Res2008
18269479Diagnosis and management of sebaceous carcinoma: an Australian experience.ANZ J Surg2008
17606713Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.Clin Cancer Res2007
16684332Metaplastic ossification in mammary fibroadenoma.Breast J2006
15487450Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma.Am J Clin Pathol2004
15372052Antimony concentrations in nodal tissue can confirm sentinel node identity.Mod Pathol2004
15221927Pathology of melanocytic lesions: new, controversial, and clinically important issues.J Surg Oncol2004
15305156Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens.Melanoma Res2004
  • 1 - 50 of 50

Recommended Authors

University of California San Diego
Career Start Year 2010
Number of shared co-authors 0
12235University of Miami Miller School of Medicine
Career Start Year 2007
Number of shared co-authors 0
Princess Margaret Cancer Centre
Career Start Year 2006
Number of shared co-authors 0
Tufts Medical Center
Career Start Year 2004
Number of shared co-authors 0
Diagnostic and Research Institute of Pathology, Medical University of Graz
Career Start Year 2003
Number of shared co-authors 1
Uppsala University
Career Start Year 2002
Number of shared co-authors 0
Department of Pathology and Laboratory Medicine Aga Khan University Hospital Karachi
Career Start Year 2001
Number of shared co-authors 0
1Rijnstate Hospital
Career Start Year 2001
Number of shared co-authors 0
University of Virginia Department of Pathology
Career Start Year 2001
Number of shared co-authors 0
Institute of Pathology, Friedrich-Alexander University Erlangen-Nurnberg (FAU)
Career Start Year 2000
Number of shared co-authors 3
Royal Jubilee Hospital, University of British Columbia
Career Start Year 2000
Number of shared co-authors 0
Seoul St. Mary's Hospital, The Catholic University of Korea
Career Start Year 1999
Number of shared co-authors 0
Wayne State University School of Medicine
Career Start Year 1999
Number of shared co-authors 0
Inha University Hospital
Career Start Year 1999
Number of shared co-authors 0
Schulich School of Medicine & Dentistry, Western University
Career Start Year 1998
Number of shared co-authors 1
Kansas City VA Medical Center
Career Start Year 1998
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 2
Prince of Wales Hospital
Career Start Year 1995
Number of shared co-authors 3
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic
Career Start Year 1994
Number of shared co-authors 3
Washington University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
Brigham and Women's Hospital and Harvard Medical School
Career Start Year 1993
Number of shared co-authors 1
Jonsson Comprehensive Cancer Center, University of California los angeles
Career Start Year 1992
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1989
Number of shared co-authors 4
Thomas Jefferson University Hospital
Career Start Year 1988
Number of shared co-authors 4
National Cancer Institute, National Institutes of Health
Career Start Year 1987
Number of shared co-authors 0
University of Kansas
Career Start Year 1985
Number of shared co-authors 0
University Hospitals Birmingham NHS Foundation Trust
Career Start Year 1984
Number of shared co-authors 2
Chugai Pharmaceutical Co. Ltd.
Career Start Year 1984
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 1977
Number of shared co-authors 5
Oita University
Career Start Year 1965
Number of shared co-authors 0

Collaborators

Westmead Hospital
Co-authored papers 18
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 14
Peter MacCallum Cancer Centre
Co-authored papers 14
Westmead Clinical School, University of Sydney
Co-authored papers 13
Co-authored papers 12
Peter MacCallum Cancer Centre
Co-authored papers 11
University of British Columbia
Co-authored papers 10
University of Calgary
Co-authored papers 10
University of British Columbia
Co-authored papers 10
Westmead Hospital
Co-authored papers 9
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 9
University of British Columbia
Co-authored papers 8
Pomeranian Medical University
Co-authored papers 8
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 8
Co-authored papers 8
College of Nursing, University of South Florida
Co-authored papers 8
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 8
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 8
Mayo Clinic College of Medicine
Co-authored papers 8
University of Cambridge
Co-authored papers 8
University of Cambridge
Co-authored papers 8
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 8
Westmead Hospital
Co-authored papers 7
Pathologisches Institut, Universitatsklinikum Heidelberg
Co-authored papers 7
Eberhard Karls University Tubingen
Co-authored papers 7
UCL EGA Institute for Women's Health, University College London
Co-authored papers 7
Mayo Clinic
Co-authored papers 7
University of Hawaii Cancer Center
Co-authored papers 7
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 7
Peter MacCallum Cancer Centre
Co-authored papers 6